Bridgewater Associates’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.48M Buy
59,733
+11,356
+23% +$729K 0.02% 499
2026
Q1
$2.73M Buy
+48,377
New +$3.15M 0.01% 585
2025
Q4
Sell
-59,104
Closed -$2.88M 1112
2025
Q3
$2.88M Buy
59,104
+12,820
+28% +$794K 0.01% 633
2025
Q2
$3.45M Buy
46,284
+24,764
+115% +$1.64M 0.01% 369
2025
Q1
$1.37M Buy
21,520
+16,128
+299% +$1.1M 0.01% 490
2024
Q4
$421K Sell
5,392
-2,434
-31% -$196K ﹤0.01% 595
2024
Q3
$629K Sell
7,826
-35,747
-82% -$2.89M ﹤0.01% 666
2024
Q2
$3.6M Sell
43,573
-3,206
-7% -$282K 0.02% 419
2024
Q1
$3.99M Sell
46,779
-7,960
-15% -$625K 0.02% 407
2023
Q4
$4.68M Sell
54,739
-5,413
-9% -$468K 0.03% 374
2023
Q3
$5.39M Buy
60,152
+4,957
+9% +$443K 0.03% 351
2023
Q2
$4.7M Sell
55,195
-6,434
-10% -$544K 0.03% 320
2023
Q1
$5.1M Buy
61,629
+2,102
+4% +$170K 0.03% 306
2022
Q4
$4.68M Sell
59,527
-21,454
-26% -$1.72M 0.03% 372
2022
Q3
$6M Sell
80,981
-64
-0.1% -$4.59K 0.03% 343
2022
Q2
$5.28M Buy
81,045
+7,552
+10% +$447K 0.02% 470
2022
Q1
$4.65M Buy
73,493
+17,518
+31% +$953K 0.02% 491
2021
Q4
$2.97M Buy
55,975
+8,306
+17% +$506K 0.02% 406
2021
Q3
$3.37M Sell
47,669
-4,236
-8% -$267K 0.02% 352
2021
Q2
$3.46M Buy
+51,905
New +$3.67M 0.02% 400

Other funds holding HAE

Bridgewater Associates's HAE Position: Q2 2026 in Review

Bridgewater Associates increased its Haemonetics (HAE) stake by 23% in Q2 2026, buying an estimated $729K and bringing the position to 59,733 shares worth $4.48M. The position accounts for 0.02% of the portfolio, ranked #499.

Bridgewater Associates first reported a position in HAE in Q2 2021 and has held it in 20 quarters since. The position peaked at $6M in Q3 2022. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Bridgewater Associates held 59,733 shares of Haemonetics worth $4.48M as of Q2 2026.
  • Bridgewater Associates bought 11,356 Haemonetics shares in Q2 2026, an estimated $729K.
  • Haemonetics made up 0.02% of Bridgewater Associates's portfolio in Q2 2026, its #499 holding.
  • Bridgewater Associates first reported a position in Haemonetics in Q2 2021 and has held it in 20 quarters since.
  • Bridgewater Associates's Haemonetics position peaked at $6M in Q3 2022.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.